- Home
- DOUG vs NTHI Comparison
DOUG vs NTHI Comparison
Compare DOUG & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | NTHI |
|---|---|---|
| Founded | 1911 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.1M | 193.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DOUG | NTHI |
|---|---|---|
| Price | $2.66 | $8.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 533.5K | 52.1K |
| Earning Date | 03-09-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,030,928,000.00 | $59,990.00 |
| Revenue This Year | $17.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.67 | N/A |
| 52 Week Low | $1.48 | $3.20 |
| 52 Week High | $3.20 | $25.00 |
Technical Indicators
Market Signals| Indicator | DOUG | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 48.39 |
| Support Level | $2.51 | $7.99 |
| Resistance Level | $2.78 | $8.83 |
| Average True Range (ATR) | 0.15 | 0.80 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 49.33 | 25.37 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).